Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30124212 | 1.00 | CAPN1 (0.42) | CAPN1GRM4GRM1PARP10PARP11 | |
| SCHEMBL30124431 | 0.90 | CAPN1 (0.40) | CAPN1GRM4GRM1PARP10PARP11 | |
| SCHEMBL30124869 | 0.88 | ROS1 (0.33) | CAPN1GRM4GRM1HSD17B13CSNK1D | |
| SCHEMBL24720126 | 0.88 | ROS1 (0.33) | CAPN1GRM4GRM1HSD17B13CSNK1D | |
| SCHEMBL30124439 | 0.88 | CAPN1 (0.37) | CAPN1GRM4GRM1PARP10PARP11 | |
| SCHEMBL24720559 | 0.86 | KMO (0.37) | GRM4GRM1COMTKMO | |
| SCHEMBL24720266 | 0.85 | ROS1 (0.44) | CAPN1COMTCSNK1DCSNK1EEPHB4 | |
| SCHEMBL24719597 | 0.85 | KMO (0.37) | GRM4GRM1COMTKMO | |
| SCHEMBL24720319 | 0.85 | NMT1 (0.39) | CSNK1D | |
| SCHEMBL30124605 | 0.85 | ROS1 (0.44) | CAPN1COMTCSNK1DCSNK1EEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | CAPN1 4297/4885GRM4 4722/4885GRM1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.